Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study
- 1Chulalongkorn University Faculty of Medicine
Abstract
Non-muscle invasive bladder cancer (NMIBC) exhibits high recurrence, necessitating frequent invasive surveillance. Urine DNA methylation profiling represents a promising non-invasive biomarker approach for early detection and monitoring. This pilot study aimed to investigate urine DNA methylation patterns in NMIBC among Thai patients. Five patients with high-grade NMIBC and three healthy volunteers were enrolled, and midstream urine and blood samples were collected prior to transurethral resection of bladder tumor (TUR-BT). Urine cell-free DNA (cfDNA) was extracted, mechanically sheared from an atypical peak of approximately 400 bp to an optimal target length of 150-200 bp, and analyzed using cell-free methylated DNA immunoprecipitation followed by high-throughput sequencing (cfMeDIP-seq). Differentially methylated regions (DMRs) were identified between NMIBC and controls, and principal component analysis (PCA) was performed. A total of 82 DMRs were identified (adjusted P < 0.001), including 76 hypermethylated and 6 hypomethylated regions, with IRX4, TBX5, and MIR124-3 representing the top hypermethylated genes. To account for cohort heterogeneity, a refined subset analysis excluding two outlier samples (UC2 and UC3) was performed, revealing 476 significant DMRs (449 hypermethylated). PCA demonstrated clear, robust segregation between NMIBC and controls, highlighting MIR124-3, IRX4, and LHX1-DT as the most significantly hypermethylated targets. Our findings demonstrate that urine cfDNA methylation profiling can robustly distinguish NMIBC from healthy controls, highlighting MIR124-3, IRX4, and LHX1-DT as highly promising, demographic-specific biomarkers. This non-invasive approach successfully bypasses the degradative limits of traditional bisulfite conversion and establishes a technically validated foundation for clinical surveillance and diagnostics
Related
- Urinary dual-site proenkephalin (PENK) methylation testing for detection of high-grade or invasive recurrence during surveillance of non-muscle-invasive bladder cancer
- Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer
- Contrasting pandemic era trajectories of dengue; chikungunya; and hand, foot, and mouth disease in Thailand using national surveillance findings, 2016–2025
- Molecular surveillance of Plasmodium vivax drug resistance genes in Kanchanaburi province, Thailand, from 2022 to 2025
- Household representatives’ understanding of dengue solutions and larval indices surveillance systems in southern Thailand: A mixed methods study
BibTeX
@misc{watcharawitayakul2026urine,
title = {{Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study}},
author = {T. Watcharawitayakul and J. Ophanurak and D. Sowanthip and P. Somparn and T. Pisitkun and P. Sainamthip},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.18.26363402},
url = {https://www.medrxiv.org/content/10.64898/2026.09.18.26363402v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Urine DNA methylation as a potential diagnostic and surveillance tool in non-muscle invasive bladder cancer in Thailand: A pilot study
AU - T. Watcharawitayakul
AU - J. Ophanurak
AU - D. Sowanthip
AU - P. Somparn
AU - T. Pisitkun
AU - P. Sainamthip
PY - 2026
DA - 2026/09/18
PB - medRxiv
DO - 10.64898/2026.09.18.26363402
UR - https://www.medrxiv.org/content/10.64898/2026.09.18.26363402v1
AB - Non-muscle invasive bladder cancer (NMIBC) exhibits high recurrence, necessitating frequent invasive surveillance. Urine DNA methylation profiling represents a promising non-invasive biomarker approach for early detection and monitoring. This pilot study aimed to investigate urine DNA methylation patterns in NMIBC among Thai patients. Five patients with high-grade NMIBC and three healthy volunteers were enrolled, and midstream urine and blood samples were collected prior to transurethral resection of bladder tumor (TUR-BT). Urine cell-free DNA (cfDNA) was extracted, mechanically sheared from an atypical peak of approximately 400 bp to an optimal target length of 150-200 bp, and analyzed using cell-free methylated DNA immunoprecipitation followed by high-throughput sequencing (cfMeDIP-seq). Differentially methylated regions (DMRs) were identified between NMIBC and controls, and principal component analysis (PCA) was performed. A total of 82 DMRs were identified (adjusted P < 0.001), including 76 hypermethylated and 6 hypomethylated regions, with IRX4, TBX5, and MIR124-3 representing the top hypermethylated genes. To account for cohort heterogeneity, a refined subset analysis excluding two outlier samples (UC2 and UC3) was performed, revealing 476 significant DMRs (449 hypermethylated). PCA demonstrated clear, robust segregation between NMIBC and controls, highlighting MIR124-3, IRX4, and LHX1-DT as the most significantly hypermethylated targets. Our findings demonstrate that urine cfDNA methylation profiling can robustly distinguish NMIBC from healthy controls, highlighting MIR124-3, IRX4, and LHX1-DT as highly promising, demographic-specific biomarkers. This non-invasive approach successfully bypasses the degradative limits of traditional bisulfite conversion and establishes a technically validated foundation for clinical surveillance and diagnostics
ER -